心肌梗塞后左心室血栓的抗凝固策略:一篇评论
Adam Folman1, Nicola Toukan1, Ofer M Kobo1,2
1Division of Cardiovascular Medicine, Hillel Yaffe Medical Center, Hadera 3820302, Israel.
Journal of clinical medicine
|November 27, 2025
概括
直接口服抗凝剂 (DOACs) 在心肌梗塞 (MI) 后治疗左心室血栓 (LVT) 有望,提供比华法林更好的凝块分辨率和更低的中风风险. 为了获得最终的指导,还需要进一步的研究.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 血栓形成研究研究
背景情况:
- 左心室血栓 (LVT) 是心肌梗塞 (MI) 后的一种严重并发症.
- 华法林一直是标准的抗凝剂,但它有局限性.
- 直接口服抗凝剂 (DOAC) 正在作为替代品出现.
研究的目的:
- 审查目前关于LVT后MI抗凝策略的证据.
- 为了比较DOACs与华法林的疗效和安全性.
- 发现当前研究中的差距,并指导未来的研究.
主要方法:
- 对12项研究的系统审查 (9个回顾性队列,3个RCT).
- 对患者群体的分析,从单中心队列到大型注册表.
- 结局结果的比较,包括血栓溶解,血栓栓塞事件,死亡率和出血.
主要成果:
- 与华法林相比,DOACs显示出较高的血栓分辨率.
- DOAC与较低的中风和全身栓塞率有关.
- 与华法林相比,DOACs的死亡率和大出血风险略有降低.
结论:
- DOACs可能提供可比的疗效和改善的安全性为LVT后MI.
- 目前的证据受限于小型,低功率的随机试验.
- 在等待更大规模的研究之前,建议进行个性化治疗,平衡风险和益处.
相关概念视频
Venous Thrombosis III: Interprofessional Care
268
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
268
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
286
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
286
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Acute Coronary Syndrome IV: Interprofessional Care
203
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
203
Angina IV: Management
222
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
222
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K


